# Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients

> **NCT02639143** · PHASE4 · COMPLETED · sponsor: **First Affiliated Hospital of Harbin Medical University** · enrollment: 50 (actual)

## Conditions studied

- Inflammation
- Thrombosis

## Interventions

- **DRUG:** ticagrelor
- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT02639143
- **Lead sponsor:** First Affiliated Hospital of Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639143, "Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02639143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*